Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71462 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Cheng Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 230 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: This research is funded by Hunan Provincial Natural Science Foundation, National Natural Science Foundation of China, Foundation for Young Talents in Higher Education of Guangdong.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are nanoscale, membrane‐bound particles that transport diverse biomolecules‐including proteins, nucleic acids, lipids, and metabolites‐between cells, thereby orchestrating key processes in cancer progression. Tumor‐derived EVs modulate angiogenesis, epithelial‐to‐mesenchymal transition, extracellular matrix remodeling, fibroblast activation, and immune evasion, shaping the tumor microenvironment, and driving metastasis as well as therapy resistance. With their stability in biofluids and cargo reflective of cellular origin, EVs have emerged as powerful non‐invasive biomarkers for early detection, disease monitoring, and prognosis across multiple cancer types. Recent advances in enrichment, characterization, and molecular profiling technologies‐ranging from ultracentrifugation and microfluidics to proteomics, RNA sequencing, and surface‐enhanced Raman spectroscopy, have greatly expanded the diagnostic potential of EVs. Integration with machine learning further enhances sensitivity, specificity, and tumor classification, while multiomic and multiplex platforms enable high‐throughput and clinically relevant applications. This review highlights the multifaceted roles of EVs in cancer biology, catalogs emerging biomarkers, and compares state‐of‐the‐art detection technologies, offering a comprehensive reference for advancing EV‐based diagnostics and precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
- Reproductive and Genetic Medicine Department, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
- School of Chemistry and Chemical Engineering, Guizhou University, Guiyang, China.
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical Uni…
ORCID-Profile: Juan Peng, Chao Kang, Ya-Juan Liu
Förderung
- This research is funded by Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Foundation for Young Talents in Higher Education of Guangdong
- Guangzhou Basic and Applied Basic Research Foundation
- Guangdong Basic and Applied Basic Research Foundation General Project
Zitieren
APA
Wang, C., Peng, J., Xie, S., Kang, C., & Liu, Y. J. (2026). Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71462
Vancouver
Wang C, Peng J, Xie S, Kang C, Liu YJ. Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71462
BibTeX
@article{Wang2026,
author = {Wang, Cheng and Peng, Juan and Xie, Sichong and Kang, Chao and Liu, Ya-Juan},
title = {Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71462}
}
EUVIMED